Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
AssigneesDeutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Universitaetsklinikum Heidelberg
InventorsAna Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
Claims6
A method for treating an individual with high grade glioma, comprising administering an agent that neutralizes CD95 activity to an individual with high grade glioma, wherein said agent is a CD95 ligand (CD95L) inhibitor comprising
- a fusion protein comprising the extracellular domain of CD95 and a human Fc domain.
Dependencies are inferred from the claim text.